Cardiff Oncology, Inc. (CRDF)
0.9073
-0.02
(-2.23%)
USD |
NASDAQ |
Oct 23, 16:00
0.9006
-0.01
(-0.74%)
After-Hours: 20:00
Cardiff Oncology Profit Margin (Quarterly) : -8.88K% for June 30, 2026
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -8.88K% |
| March 31, 2026 | -30.11K% |
| December 31, 2025 | -2.97K% |
| September 30, 2025 | -9.38K% |
| June 30, 2025 | -11.52K% |
| March 31, 2025 | -12.32K% |
| December 31, 2024 | -7.81K% |
| September 30, 2024 | -7.18K% |
| June 30, 2024 | -7.23K% |
| March 31, 2024 | -4.88K% |
| December 31, 2023 | -5.99K% |
| September 30, 2023 | -6.90K% |
| June 30, 2023 | -10.32K% |
| March 31, 2023 | -13.52K% |
| December 31, 2022 | -6.79K% |
| September 30, 2022 | -9.22K% |
| June 30, 2022 | -11.48K% |
| March 31, 2022 | -14.86K% |
| December 31, 2021 | -7.10K% |
| September 30, 2021 | -8.04K% |
| June 30, 2021 | -9.94K% |
| March 31, 2021 | -7.19K% |
| December 31, 2020 | -5.53K% |
| September 30, 2020 | -3.30K% |
| June 30, 2020 | -9.68K% |
| Date | Value |
|---|---|
| March 31, 2020 | -6.04K% |
| December 31, 2019 | -4.58K% |
| September 30, 2019 | -8.01K% |
| June 30, 2019 | -10.77K% |
| March 31, 2019 | -6.30K% |
| December 31, 2018 | -5.33K% |
| September 30, 2018 | -4.26K% |
| June 30, 2018 | -3.35K% |
| March 31, 2018 | -4.78K% |
| December 31, 2017 | -1.39K% |
| September 30, 2017 | -3.48K% |
| June 30, 2017 | -7.89K% |
| March 31, 2017 | -10.53K% |
| December 31, 2016 | -12.57K% |
| September 30, 2016 | -11.44K% |
| June 30, 2016 | -9.87K% |
| March 31, 2016 | -8.52K% |
| December 31, 2015 | -9.34K% |
| September 30, 2015 | -4.77K% |
| June 30, 2015 | -20.65K% |
| March 31, 2015 | -5.65K% |
| December 31, 2014 | -8.36K% |
| September 30, 2014 | -9.40K% |
| June 30, 2014 | -1.94K% |
| March 31, 2014 | -2.87K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 10.23% |
| Alnylam Pharmaceuticals, Inc. | 12.74% |
| Anika Therapeutics, Inc. | 10.15% |
| Savara, Inc. | -- |
| Vericel Corp. | 2.85% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -93.57% |
| Return on Assets | -69.56% |
| Return on Invested Capital | -91.79% |
| Gross Profit Margin (Quarterly) | -113.5% |
| Operating Margin (Quarterly) | -9.25K% |
| Return on Net Operating Assets | -2.39K% |